Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
Identifieur interne : 000E02 ( Istex/Curation ); précédent : 000E01; suivant : 000E03Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
Auteurs : Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-08-15.
English descriptors
Abstract
Perhaps the most important unmet need in Parkinson's disease (PD) is the ability to slow or prevent progression of the neurodegeneration that underlies the motor and nonmotor features of this disorder. Pramipexole, a dopamine agonist used for the symptomatic treatment of PD, has demonstrated neuroprotective properties in laboratory studies. The PRamipexole On Underlying Disease (PROUD) study is a randomized, double‐blind clinical trial evaluating the ability of pramipexole to modify disease progression using a delayed‐start design. PD patients (n = 535) with mean age 62.5 years, mean duration since diagnosis of 4.4 months, and mean total Unified Parkinson's disease Rating Scale (UPDRS) score of 24.5 were recruited. In Phase I, patients were randomly assigned to be titrated to 1.5 mg pramipexole or placebo and maintained on study drug for 6–9 months. In Phase II, all patients were titrated to 1.5 mg pramipexole and maintained on study drug until the end of the study at 15 months. No rescue medication was allowed in the protocol. The primary endpoint is the change in total UPDRS score (parts I–III) from baseline to 15 months. A range of secondary endpoints separately assess UPDRS subscales, quality of life, depression, and impulse control disorders. A sub‐study examined dopamine transporter uptake scans at baseline and 15 months. The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23143
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E02
Links to Exploration step
ISTEX:7B5F1EFF37468DE770370D07C19C11E1F8E02073Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Albrecht, Stefan" sort="Albrecht, Stefan" uniqKey="Albrecht S" first="Stefan" last="Albrecht">Stefan Albrecht</name><affiliation wicri:level="1"><mods:affiliation>Boehringer Ingelheim GmbH, CD Medical Affairs CNS, Ingelheim, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim GmbH, CD Medical Affairs CNS, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, University of Naples, Federico II and IDC‐Hermitage‐Capodimonte, Naples, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Naples, Federico II and IDC‐Hermitage‐Capodimonte, Naples</wicri:regionArea></affiliation></author><author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation wicri:level="1"><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7B5F1EFF37468DE770370D07C19C11E1F8E02073</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23143</idno><idno type="url">https://api.istex.fr/document/7B5F1EFF37468DE770370D07C19C11E1F8E02073/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E02</idno><idno type="wicri:Area/Istex/Curation">000E02</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea></affiliation></author><author><name sortKey="Albrecht, Stefan" sort="Albrecht, Stefan" uniqKey="Albrecht S" first="Stefan" last="Albrecht">Stefan Albrecht</name><affiliation wicri:level="1"><mods:affiliation>Boehringer Ingelheim GmbH, CD Medical Affairs CNS, Ingelheim, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim GmbH, CD Medical Affairs CNS, Ingelheim</wicri:regionArea></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, University of Naples, Federico II and IDC‐Hermitage‐Capodimonte, Naples, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Naples, Federico II and IDC‐Hermitage‐Capodimonte, Naples</wicri:regionArea></affiliation></author><author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name><affiliation wicri:level="1"><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center INSERM CIC9302 and INSERM UMR825, Toulouse University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation wicri:level="1"><mods:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Institute for Neurodegenerative Disorders, New Haven, Connecticut</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15">2010-08-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1627">1627</biblScope><biblScope unit="page" to="1632">1632</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7B5F1EFF37468DE770370D07C19C11E1F8E02073</idno><idno type="DOI">10.1002/mds.23143</idno><idno type="ArticleID">MDS23143</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinical trial</term><term>delayed‐start</term><term>neuroprotection</term><term>pramipexole</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Perhaps the most important unmet need in Parkinson's disease (PD) is the ability to slow or prevent progression of the neurodegeneration that underlies the motor and nonmotor features of this disorder. Pramipexole, a dopamine agonist used for the symptomatic treatment of PD, has demonstrated neuroprotective properties in laboratory studies. The PRamipexole On Underlying Disease (PROUD) study is a randomized, double‐blind clinical trial evaluating the ability of pramipexole to modify disease progression using a delayed‐start design. PD patients (n = 535) with mean age 62.5 years, mean duration since diagnosis of 4.4 months, and mean total Unified Parkinson's disease Rating Scale (UPDRS) score of 24.5 were recruited. In Phase I, patients were randomly assigned to be titrated to 1.5 mg pramipexole or placebo and maintained on study drug for 6–9 months. In Phase II, all patients were titrated to 1.5 mg pramipexole and maintained on study drug until the end of the study at 15 months. No rescue medication was allowed in the protocol. The primary endpoint is the change in total UPDRS score (parts I–III) from baseline to 15 months. A range of secondary endpoints separately assess UPDRS subscales, quality of life, depression, and impulse control disorders. A sub‐study examined dopamine transporter uptake scans at baseline and 15 months. The results of PROUD will provide insight into the potential for early versus delayed treatment with pramipexole to modify motor outcome at 15 months in recently diagnosed PD patients. © 2010 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000E02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:7B5F1EFF37468DE770370D07C19C11E1F8E02073
|texte= Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
}}
| This area was generated with Dilib version V0.6.23. |  |